JP2024544757A5 - - Google Patents
Info
- Publication number
- JP2024544757A5 JP2024544757A5 JP2024529287A JP2024529287A JP2024544757A5 JP 2024544757 A5 JP2024544757 A5 JP 2024544757A5 JP 2024529287 A JP2024529287 A JP 2024529287A JP 2024529287 A JP2024529287 A JP 2024529287A JP 2024544757 A5 JP2024544757 A5 JP 2024544757A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- linker
- immunoglobulin
- dba
- hinge
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163280494P | 2021-11-17 | 2021-11-17 | |
| US63/280,494 | 2021-11-17 | ||
| PCT/US2022/080043 WO2023092006A1 (en) | 2021-11-17 | 2022-11-17 | Compositions of protein complexes and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024544757A JP2024544757A (ja) | 2024-12-04 |
| JP2024544757A5 true JP2024544757A5 (enExample) | 2025-11-26 |
Family
ID=84981857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024529287A Pending JP2024544757A (ja) | 2021-11-17 | 2022-11-17 | タンパク質複合体の組成物およびその使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240366776A1 (enExample) |
| EP (1) | EP4433097A1 (enExample) |
| JP (1) | JP2024544757A (enExample) |
| KR (1) | KR20240101593A9 (enExample) |
| CN (1) | CN118555973A (enExample) |
| AU (1) | AU2022390563A1 (enExample) |
| CA (1) | CA3238260A1 (enExample) |
| IL (1) | IL312802A (enExample) |
| MX (1) | MX2024005948A (enExample) |
| TW (1) | TW202330628A (enExample) |
| WO (1) | WO2023092006A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2026517390A (ja) * | 2023-05-16 | 2026-05-29 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | Ｐｄ－１調節ｉｌ－２免疫サイトカインおよびその使用 |
| WO2026104330A1 (en) * | 2024-11-12 | 2026-05-21 | F. Hoffmann-La Roche Ag | Pd-1-regulated il-2 immunoconjugates and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7148539B2 (ja) * | 2017-04-03 | 2022-10-05 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 免疫抱合体 |
| KR102461885B1 (ko) * | 2017-04-03 | 2022-11-03 | 에프. 호프만-라 로슈 아게 | 항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체 |
| AU2018287317B2 (en) * | 2017-06-19 | 2024-06-20 | Medicenna Therapeutics Inc. | Uses and methods for IL-2 superagonists, agonists, and fusions thereof |
| US11970537B2 (en) * | 2017-12-26 | 2024-04-30 | Nanjing GenScript Biotech Co., Ltd. | Fusion protein dimer using antibody Fc region as backbone and use thereof |
| JP7778571B2 (ja) * | 2019-06-05 | 2025-12-02 | アッシャー バイオセラピューティクス， インコーポレイテッド | 免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体 |
| KR20230010251A (ko) * | 2020-05-13 | 2023-01-18 | 보넘 테라퓨틱스, 인크. | 단백질 복합체의 조성물 및 그의 사용 방법 |
-
2022
- 2022-11-17 CN CN202280076016.3A patent/CN118555973A/zh active Pending
- 2022-11-17 AU AU2022390563A patent/AU2022390563A1/en active Pending
- 2022-11-17 WO PCT/US2022/080043 patent/WO2023092006A1/en not_active Ceased
- 2022-11-17 EP EP22844606.8A patent/EP4433097A1/en active Pending
- 2022-11-17 IL IL312802A patent/IL312802A/en unknown
- 2022-11-17 TW TW111143997A patent/TW202330628A/zh unknown
- 2022-11-17 JP JP2024529287A patent/JP2024544757A/ja active Pending
- 2022-11-17 MX MX2024005948A patent/MX2024005948A/es unknown
- 2022-11-17 KR KR1020247016162A patent/KR20240101593A9/ko active Pending
- 2022-11-17 CA CA3238260A patent/CA3238260A1/en active Pending
-
2024
- 2024-05-16 US US18/665,678 patent/US20240366776A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ma et al. | Bispecific antibodies: from research to clinical application | |
| KR102651761B1 (ko) | 암 치료용 결합 분자 | |
| CA3031082C (en) | Bispecific proteins and methods for preparing same | |
| JP2021508469A5 (enExample) | ||
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| KR20220156526A (ko) | 조작된 항-her2 이중특이성 단백질 | |
| JP2024521701A (ja) | 抗ｃｄ１３７抗体及びその使用方法 | |
| JP2022506761A5 (enExample) | ||
| WO2020169062A1 (zh) | 抗pd-l1抗体及其用途 | |
| US20250154265A1 (en) | Anti-cMET Antibodies and Methods of Use | |
| CA3155293A1 (en) | System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies | |
| WO2014072741A1 (en) | Humanised antibody and method of production thereof | |
| US20240124607A1 (en) | Proteins binding nkg2d, cd16, and ceacam5 | |
| EP4559932A1 (en) | Multispecific antibody and use thereof | |
| JP2024519078A (ja) | 抗ｃｅａ抗体及びその使用方法 | |
| WO2023186112A1 (zh) | 靶向ceacam和cd3的多特异性抗体及其用途 | |
| JP2024508597A5 (enExample) | ||
| US20240392035A1 (en) | Engineered anti-her2 bispecific proteins | |
| RU2024114224A (ru) | Композиции белковых комплексов и способы их применения | |
| JP2025538377A (ja) | 抗ｉｌ－２抗体の使用方法 | |
| WO2024054418A1 (en) | Sequence optimization of a pd1 blocking antibody | |
| WO2025024780A1 (en) | Antibodies that bind gamma-delta t cell receptors for the treatment of cancer | |
| JP2025518049A (ja) | 抗ｔｉｇｉｔ抗体製剤 | |
| HK40076446B (en) | 4-1bb binding protein and application thereof | |
| RU2024116487A (ru) | Биспецифическое антитело и его применение |